Buy & Sell Kellogg Company (K) – Kellogg Company Price Today
Key Stats
- $29.03BMarket Cap
- Consumer StaplesSector
- -3M Drawdown
- $34.99BEnterprise Value
- 2.78%Dividend Yield
- 107 daysTypical Hold Time
Kellogg Company (K) is currently valued at a market capitalization of $29.03B, with an enterprise value of $34.99B. Over the past 52 weeks, Kellogg Company has traded between a low of $76.96 and a high of $83.64, highlighting its annual price range. Kellogg Company offers a dividend yield of 2.78%, with the most recent dividend of $0.58 paid on 01 Dec 25. On average, investors hold Kellogg Company for approximately 107 days, indicating typical investor behavior on the platform.
About Kellogg Company
Founded in 1906, Kellogg is a leading global manufacturer and marketer of cereal, cookies, crackers, and other packaged foods. Its offerings are manufactured in 21 countries and marketed in more than 180 countries. Its product mix includes well-known brands such as Special K, Frosted Flakes, Froot Loops, Rice Krispies, Pop-Tarts, Eggo, Kashi, and Morningstar Farms. The firm added the Pringles brand to its mix in 2012. Sales outside its home turf account for around 40% of Kellogg's consolidated sales base. The firm intends to split its global snacking arm from its North American cereal and plant-based alternative segments by the end of calendar 2023.
Most Recent News
Boston Scientific invests $1.5B for stake in MiRus, targeting advanced aortic stenosis treatment.
Boston Scientific has invested $1.5 billion to acquire about a 34% stake in MiRus, gaining exclusive rights to its investigational transcatheter aortic valve replacement (TAVR) system designed for severe aortic stenosis. The SIEGEL valve features a n...
Elliott sees hidden value in Bio-Rad via $5B Sartorius stake amid share price slump
Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories, which develops medical instruments and software. Bio-Rad's founding family retains majority voting control, complicating activist efforts. Elliott ...
Regeneron's melanoma trial fails, stock drops over 10%, investors urged to explore legal options.
Regeneron Pharmaceuticals announced that its Phase 3 melanoma trial combining fianlimab and Libtayo did not meet the primary endpoint against Keytruda, causing the stock to fall more than 10%. Prior optimism from company executives about the trial's ...
